D. Gerber

Xian-Jin Xie, S. Ramalingam, D. Gerber, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials

Xian-Jin Xie, D. Gerber, Jingsheng Yan, 2017, Clinical lung cancer.

Should criteria for inclusion in cancer clinical trials be expanded?

E. Halm, D. Gerber, S. Pruitt, 2015, Journal of comparative effectiveness research.

Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center.

Yang Xie, D. Gerber, Jingsheng Yan, 2012, Clinical lung cancer.

Development and Validation of a Nomogram Prognostic Model for SCLC Patients

Shidan Wang, Lin Yang, Guanghua Xiao, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Development and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients

Shidan Wang, Lin Yang, Guanghua Xiao, 2018, bioRxiv.

Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse Population

Yang Xie, D. Gerber, D. Rasco, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection

E. Halm, Shidan Wang, Yang Xie, 2020, Cancer medicine.

Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases

J. Reisch, D. Gerber, Elizabeth McGehee, 2019, Clinical lung cancer.

Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer

D. Gerber, D. Sher, L. Nedzi, 2019, Oncology.

Immunotherapy Use in Patients With Lung Cancer and Comorbidities.

J. Minna, D. Gerber, Helen Mayo, 2020, Cancer journal.

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors

N. Ibrahim, D. Gerber, A. Stopeck, 2011, Clinical Cancer Research.

Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer

Quyen N. Do, B. Faubert, R. Deberardinis, 2020, Clinical Cancer Research.

ALK mutation and inhibition in lung cancer

D. Gerber, T. Le, Tri Le, 2017 .

Radiation-induced KRAS G12V mutant lung adenocarcinoma in a never smoker

H. Choy, D. Gerber, D. Oliver, 2016 .

Docetaxel and bavituximab in nonsquamous NSCLC 1 Docetaxel Plus Bavituximab in Previously Treated , Advanced Nonsquamous Non – small-cell Lung Cancer

D. Gerber, D. Spigel, C. Belani, 2016 .

Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer.

D. Gerber, D. Spigel, C. Belani, 2016, Clinical lung cancer.

Cancer Therapeutics Insights BIBF 1120 ( Nintedanib ) , a Triple Angiokinase Inhibitor , Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

D. Gerber, R. Brekken, Katherine T. Ostapoff, 2013 .

BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

D. Gerber, R. Brekken, Katherine T. Ostapoff, 2013, Molecular Cancer Therapeutics.

Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment.

D. Gerber, P. Thorpe, P. DeRose, 2011, Immunotherapy.

Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?

J. Minna, D. Gerber, M. V. von Itzstein, 2020, EBioMedicine.

Miscellaneous agents--cytotoxics and hormonal agents.

D. Gerber, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer

D. Gerber, I. Bondarenko, W. Su, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?

D. Gerber, Arjun Gupta, S. Khanna, 2020, PloS one.

A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.

D. Gerber, S. Rashdan, 2017, Translational cancer research.

Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.

P. Iyengar, R. Timmerman, D. Gerber, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence and Significance of Potential Pharmacokinetic Drug–Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials

D. Gerber, C. Alvarez, C. Selby, 2021, Clinical Drug Investigation.

Autoimmunity, Checkpoint Inhibitor Therapy and Immune-related Adverse Events: A Review.

D. Gerber, Shaheen Khan, 2020, Seminars in cancer biology.

A randomized trial of mail and email recruitment strategies for a physician survey on clinical trial accrual

E. Halm, C. Skinner, D. Gerber, 2020, BMC Medical Research Methodology.

Conceptual Model for Accrual to Cancer Clinical Trials.

C. Skinner, S. C. Lee, D. Gerber, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Consent timing and experience: modifiable factors that may influence interest in clinical research.

C. Skinner, Yang Xie, D. Gerber, 2012, Journal of oncology practice.

The impact of consenter characteristics and experience on patient interest in clinical research.

C. Skinner, D. Gerber, D. Rasco, 2009, The oncologist.

Oligometastatic Non-Small-Cell Lung Cancer: How Should We Define and Manage It?

D. Gerber, 2018, Journal of oncology practice.

transplantation: implications for VTE prevention and bleeding among 1514 patients undergoing hematopoietic stem cell The incidence of and risk factors for venous thromboembolism (VTE)

J. Segal, D. Gerber, Richard J. Jones, 2013 .

Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options.

D. Gerber, Lei Xuan, Saad A. Khan, 2016, JAMA oncology.

Definition and Coordination of Roles and Responsibilities Among Cancer Center Clinic and Research Personnel.

D. Gerber, S. C. Craddock Lee, T. Reimer, 2020, Journal of oncology practice.

Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: a retrospective cohort study

D. Gerber, Arjun Gupta, C. Alvarez, 2020, Supportive Care in Cancer.

A reevaluation of CD22 expression in human lung cancer.

Laurentiu M. Pop, Iliodora V. Pop, J. Minna, 2014, Cancer research.

Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial.

Xian-Jin Xie, A. Christie, P. Iyengar, 2015, International journal of radiation oncology, biology, physics.

Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors

Yang Xie, D. Gerber, Jiong Cai, 2022, Cancer Immunology, Immunotherapy.

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Patient and provider perspectives on delivery of oral cancer therapies.

S. C. Lee, D. Gerber, C. Murphy, 2019, Patient education and counseling.

Survival of cancer survivors with a new pancreatic cancer diagnosis

E. Halm, D. Heitjan, D. Gerber, 2022, Cancer medicine.

Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.

Jun Yao, J. Minna, M. Peyton, 2016, Cancer cell.

Impact of prior cancer on eligibility for lung cancer clinical trials.

E. Halm, Andrew L Laccetti, D. Gerber, 2014, Journal of the National Cancer Institute.

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

C. Henschke, D. Yankelevitz, J. Minna, 2022, Cancer Cell.

Oncologic emergencies and urgencies: A comprehensive review

D. Gerber, D. Kyriacou, C. Baugh, 2022, CA: a cancer journal for clinicians.

Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

D. Gerber, Carrie Lee, J. Schiller, 2021, Frontiers in Oncology.

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era.

D. Gerber, M. V. von Itzstein, C. Selby, 2022, Clinical lung cancer.

Enhancing access to and diversity in cancer clinical trials through a financial reimbursement program: Protocol to evaluate a novel program.

Jasmin A. Tiro, P. Leavey, D. Gerber, 2022, Contemporary clinical trials.

Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts.

Jon A. Anderson, D. Mathews, D. Gerber, 2015, American journal of nuclear medicine and molecular imaging.

Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis

J. Segal, A. Olivi, D. Gerber, 2007, Cancer.

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

L. Sequist, D. Costa, R. Ramlau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation

J. Sarkaria, Yan Liu, Shwu‐Yuan Wu, 2022, Nature Cell Biology.

Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report

D. Gerber, M. V. von Itzstein, Amrit S. Gonugunta, 2022, Journal of Medical Case Reports.

Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.

S. Gettinger, L. Crinò, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors

Yang Xie, D. Gerber, Jiong Cai, 2022, Cancer Immunology, Immunotherapy.

Humoral and cellular correlates of a novel immune-related adverse event and its treatment

D. Gerber, Quanzhen Li, J. Farrar, 2021, Journal for ImmunoTherapy of Cancer.

Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.

M. White, D. Gerber, P. Scaglioni, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role of Nuclear Export Functions in Normal Cell Physiology and Cancer

M. White, D. Gerber, P. Scaglioni, 2017 .

Phase 0 Trial of Itraconazole for Early-Stage Non-Small Cell Lung Cancer

D. Gerber, 2015 .

Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study

E. Diamandis, J. Heymach, D. Gerber, 2022, Clinical chemistry and laboratory medicine.

NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers

Xian-Jin Xie, D. Gerber, D. Boothman, 2019, Clinical Cancer Research.

Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage

K. Westover, D. Gerber, E. Zhang-Velten, 2020, JTO clinical and research reports.

Management and future directions in non-small cell lung cancer with known activating mutations.

D. Costa, D. Gerber, L. Gandhi, 2014, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.

P. Jänne, R. Govindan, S. Mandrekar, 2015 .

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

P. Ascierto, Rajeev Sharma, J. Sosman, 2021, Journal for ImmunoTherapy of Cancer.

Axl Receptor Axis: A New Therapeutic Target in Lung Cancer

L. Byers, D. Gerber, R. Brekken, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

S. Gettinger, F. Shepherd, D. Gerber, 2017, The Lancet. Oncology.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology

G. Sledge, D. Gerber, M. Smith, 2020, Cancer.

Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

P. Iyengar, K. Westover, H. Choy, 2018, JAMA oncology.

Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer

E. Halm, Andrew L Laccetti, D. Gerber, 2017, British Journal of Cancer.

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

Yang Xie, D. Gerber, H. Kindler, 2012, Lung cancer.

Emerging monoclonal antibody therapies for malignant gliomas

D. Gerber, J. Laterra, 2007, Expert opinion on investigational drugs.

Targeting the PI3K pathway for cancer therapy.

D. Gerber, N. Sadeghi, 2012, Future medicinal chemistry.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

S. Gettinger, E. Felip, L. Crinò, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

P. Iyengar, H. Choy, R. Timmerman, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Choroid plexus papilloma—A case highlighting the challenges of extrapolating pediatric chemotherapy regimens to adult populations

D. Gerber, G. Jean, W. Dinsfriend, 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy

D. Gerber, Quanzhen Li, E. Wakeland, 2022, Cancers.

Association between immune-related adverse event timing and treatment outcomes

Yang Xie, D. Gerber, A. Cortellini, 2022, Oncoimmunology.

Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505).

W. Curran, R. Jeraj, J. Bradley, 2017, Clinical lung cancer.

Application of Information Technology to Clinical Trial Evaluation and Enrollment: A Review.

D. Gerber, Helen Mayo, Melanie A Hullings, 2021, JAMA oncology.

Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer

J. Minna, P. Iyengar, D. Gerber, 2021, Translational lung cancer research.

Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

J. Minna, D. Gerber, S. Burma, 2021, Nature Communications.

Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways

D. Gerber, D. Boothman, G. Chakrabarti, 2015, Clinical pharmacology : advances and applications.

Targeted Therapies for Lung Cancer: Clinical Experience and Novel Agents

J. Minna, D. Gerber, J. Larsen, 2011, Cancer journal.

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden

Tao Wang, D. Gerber, R. Samstein, 2020, Cell reports medicine.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

G. Giaccone, M. Krasnow, C. Rudin, 2022 .

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer

P. Jänne, R. Govindan, S. Mandrekar, 2015, Clinical Cancer Research.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Immune dysregulation in cancer patients developing immune-related adverse events

Yang Xie, D. Gerber, Quanzhen Li, 2018, British Journal of Cancer.

Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts

M. Peyton, D. Gerber, R. Brekken, 2012, Molecular Cancer Therapeutics.

Preclinical Development Stromal Platelet-Derived Growth Factor Receptor a ( PDGFR a ) Provides a Therapeutic Target Independent of Tumor Cell PDGFR a Expression in Lung Cancer Xenografts

M. Peyton, D. Gerber, R. Brekken, 2012 .

Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies

L. Sequist, J. Engelman, P. Fidias, 2016, Journal of Thoracic Oncology.

Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Jason Y. Park, Yang Xie, D. Gerber, 2020, The oncologist.

EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer

J. Minna, M. Peyton, C. Chiang, 2020, Nature Cancer.

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

J. Minna, M. Peyton, Masaya Takahashi, 2018, The Journal of clinical investigation.

EGFR inhibition in the treatment of non‐small cell lung cancer

D. Gerber, 2008, Drug development research.

Management of venous thromboembolism in patients with primary and metastatic brain tumors.

D. Gerber, S. Grossman, M. Streiff, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis.

A. Gazdar, Shidan Wang, Lin Yang, 2018, Lung cancer.

Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors

Jason Y. Park, Yang Xie, D. Gerber, 2021, Journal for ImmunoTherapy of Cancer.

Using a novel NQO1 bioactivatable drug, beta‐lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer

R. Deberardinis, Xian-Jin Xie, D. Gerber, 2017, Journal of surgical oncology.

Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.

D. Gerber, David E Gerber, Sawsan Rashdan, 2016, Annals of translational medicine.

Immune dysregulation in cancer patients developing immune-related adverse events

Yang Xie, D. Gerber, Quanzhen Li, 2018, British Journal of Cancer.

The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention.

J. Segal, D. Gerber, Richard J. Jones, 2008, Blood.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling

Yang Xie, D. Gerber, D. Sher, 2019, Head & neck.

A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).

T. Owonikoko, S. Ramalingam, D. Gerber, 2015, Lung cancer.

Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance Therapy

Yang Xie, D. Gerber, D. Rasco, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC

S. Gettinger, F. Shepherd, D. Gerber, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.

J. Sarkaria, D. Gerber, S. Burma, 2019, Neuro-oncology.

Chemotherapy for Advanced Non-small Cell Lung Cancer.

D. Gerber, M. Dietrich, 2016, Cancer treatment and research.

Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea.

D. Gerber, J. Schiller, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer.

R. Collins, D. Gerber, M. Dietrich, 2016, JAMA oncology.

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.

Chao Huang, M. Socinski, J. Neal, 2018, Lung cancer.

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

D. Gerber, P. Swanson, A. Dowlati, 2017, Lung cancer.

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

G. Giaccone, M. Socinski, M. Ahn, 2017, Lung cancer.

Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors

C. Rudin, E. Schmidt, H. Pandha, 2023, Journal for ImmunoTherapy of Cancer.

Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA.

R. Doebele, D. Gerber, T. Stinchcombe, 2022, Lung cancer.

Brief report: Preliminary clinical and molecular analysis results from a single arm phase 2 trial of brigatinib in patients with disease progression after next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in advanced ALK + non-small cell lung cancer.

R. Doebele, D. Gerber, T. Stinchcombe, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors

D. Gerber, K. Ariizumi, P. Cruz, 2019, Clinical Cancer Research.

Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

Yulei N. Wang, E. Felip, D. Gerber, 2019, Clinical Cancer Research.

Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis

Yang Xie, D. Gerber, Xin Luo, 2018, British Journal of Cancer.

Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?

D. Gerber, T. Le, Tri Le, 2019, Cancers.

Cetuximab in combination therapy: from bench to clinic

H. Choy, D. Gerber, 2010, Cancer and Metastasis Reviews.

Statistical justification of expansion cohorts in phase 1 cancer trials

Xian-Jin Xie, D. Heitjan, A. Mokdad, 2018, Cancer.

Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone

R. Deberardinis, D. Gerber, Jinming Gao, 2015, Scientific Reports.

Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

Marilyn M. Li, T. Burns, S. Ramalingam, 2019, Lung cancer.

Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy.

J. Minna, D. Gerber, S. Rashdan, 2018, The Lancet. Respiratory medicine.

Stigma among patients with lung cancer: a patient‐reported measurement model

D. Gerber, J. Ostroff, J. Schiller, 2014, Psycho-oncology.

Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.

D. Gerber, D. Rasco, H. Hamann, 2012, Patient education and counseling.

Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.

D. Gerber, Han Sun, Bercin Kutluk Cenik, 2013, Lung cancer.

ALK alterations and inhibition in lung cancer.

D. Gerber, T. Le, Tri Le, 2017, Seminars in cancer biology.

Locally Advanced Lung Cancer: An Optimal Setting for Vaccines and Other Immunotherapies

P. Iyengar, D. Gerber, 2013, Cancer journal.

Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).

D. Carbone, Melissa L. Johnson, S. Ramalingam, 2020, Clinical lung cancer.

Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis.

E. Halm, Andrew L Laccetti, D. Gerber, 2016, Lung cancer.

Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy

R. Hannan, J. Brugarolas, A. Christie, 2018, Oncoimmunology.

Maintenance therapy for advanced lung cancer: who, what, and when?

D. Gerber, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline tumour measurements predict survival in advanced non-small cell lung cancer

D. Gerber, J. Schiller, D. Ahn, 2013, British Journal of Cancer.

Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?

D. Gerber, M. Beg, Sherry Fu, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice.

D. Gerber, S. Rashdan, 2019, Translational lung cancer research.

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group

Suzanne F. Jones, B. Mahal, D. Gerber, 2021, Clinical Cancer Research.

Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition.

D. Gerber, D. Oliver, J. Sailors, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2020 .

Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies

D. Gerber, M. Axelson, 2009 .

A novel polymer gel for the delivery of local therapies to intracranial tumors: In vivo safety evaluation.

G. Gallia, D. Gerber, C. Eberhart, 2011, Journal of biomedical materials research. Part A.

Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer

Guanghua Xiao, Tao Wang, Yang Xie, 2019, Cancer informatics.

The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas.

D. Gerber, S. Grossman, L. Kleinberg, 2007, Neuro-oncology.

Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay

D. Gerber, M. Beg, D. Hsiehchen, 2021, Cancer biology & therapy.

How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis.

D. Gerber, U. Makris, Lei Xuan, 2018, Lung cancer.

The influence of medical comorbidities on the presentation and outcome of stage I-III non-small cell lung cancer.

Yang Xie, D. Gerber, Jingsheng Yan, 2010 .

Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients.

C. Rudin, H. Pandha, D. Gerber, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

How Have We Diagnosed Early-Stage Lung Cancer without Radiographic Screening? A Contemporary Single-Center Experience

D. Gerber, Jingsheng Yan, J. Yorio, 2012, PloS one.

Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).

S. Gettinger, L. Crinò, S. Ramalingam, 2016 .

Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity?

Yang Xie, D. Gerber, Jingsheng Yan, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Access to Investigational Drugs: FDA Expanded Access Programs or “Right‐to‐Try” Legislation?

D. Gerber, J. E. Adamo, K. Weatherwax, 2015, Clinical and translational science.

Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer.

Yang Xie, D. Gerber, J. Schiller, 2015, Lung cancer.

Predictors and intensity of online access to electronic medical records among patients with cancer.

Yang Xie, Beibei Chen, Jingsheng Yan, 2014, Journal of oncology practice.

Mobile Device Applications for Electronic Patient Portals in Oncology.

Jennifer Cai, Samantha Gates, Yang Xie, 2019, JCO clinical cancer informatics.

Characteristics of Patients Using Patient Portals in Oncology

Samantha Gates, Yang Xie, D. Gerber, 2018, JAMA oncology.

A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non− small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC).

David S. Shames, David E. Gerber, Jeffrey R. Infante, 2013 .

Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.

E. Halm, Andrew L Laccetti, D. Gerber, 2014, Journal of the National Cancer Institute.

Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer.

G. Bhattacharyya, D. Gerber, P. Bapsy, 2014, Lung cancer.

Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database

Shidan Wang, Yang Xie, D. Gerber, 2018, Oncotarget.

EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.

C. Rudin, M. Edelman, S. Ramalingam, 2017 .

CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.

D. de Ruysscher, S. Peters, S. Ramalingam, 2021, Clinical lung cancer.

ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

P. Jänne, R. Govindan, S. Mandrekar, 2020 .

Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors

Yang Xie, D. Gerber, R. Lu, 2019, JAMA network open.

Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer

E. Halm, D. Heitjan, D. Gerber, 2021, Cancer Medicine.

Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial.

S. Abbara, D. Gerber, H. Hamann, 2017, Contemporary clinical trials.

Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer

C. Obasaju, R. Govindan, H. Choy, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical System.

D. Gerber, H. Hamann, C. Ahn, 2020, Clinical lung cancer.

Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma.

E. Halm, D. Gerber, L. Anderson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.

J. Nieva, Melissa L. Johnson, L. Byers, 2021, Journal of Clinical Oncology.

QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.

M. Link, D. Gerber, C. Alvarez, 2019, Clinical lung cancer.

AXL Inhibitors: Status of Clinical Development

D. Gerber, S. Bhalla, 2023, Current Oncology Reports.

Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations.

Xian-Jin Xie, D. Gerber, Jingsheng Yan, 2015, The oncologist.

Hyperprogressive disease: a distinct effect of immunotherapy?

D. Gerber, V. Popat, 2019, Journal of thoracic disease.

Recent advances in radiation therapy.

T. Chan, D. Gerber, T. Chan, 2008, American Family Physician.

Estimating lead‐time bias in lung cancer diagnosis of patients with previous cancers

D. Heitjan, D. Gerber, Lei Xuan, 2018, Statistics in medicine.

Effect of Prior Cancer on Outcomes in Advanced Lung Cancer: Implications for Clinical Trial Eligibility and Accrual

E. Halm, Andrew L Laccetti, D. Gerber, 2014 .

Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC).

R. Doebele, D. Gerber, T. Stinchcombe, 2019, Journal of Clinical Oncology.

Upper lip metastasis of sarcomatoid carcinoma of the lung – an unusual site of disease: a case report

D. Gerber, J. Truelson, J. Sailors, 2017, Journal of Medical Case Reports.

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors

Laurentiu M. Pop, R. Hannan, Yuanyuan Zhang, 2023, Translational oncology.

Type and case volume of health care facility influences survival and surgery selection in cases with early‐stage non–small cell lung cancer

E. Halm, Xiaowei Zhan, Shidan Wang, 2019, Cancer.

Statin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?

Jason Y. Park, Yang Xie, D. Gerber, 2020, The oncologist.

Impact of NCI-mandated scientific review on protocol development and content.

Xian-Jin Xie, D. Gerber, Jingsheng Yan, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses

S. Gettinger, F. Shepherd, D. Gerber, 2015 .

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2019, Journal of Thoracic Oncology.

OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria.

D. Gerber, P. Forde, H. Singh, 2022, JAMA oncology.

Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials.

D. Gerber, C. Murphy, S. Pruitt, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Survival of women diagnosed with breast cancer and who have survived a previous cancer

E. Halm, D. Heitjan, D. Gerber, 2021, Breast Cancer Research and Treatment.

Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial.

D. Gerber, H. Hamann, O. Dorsey, 2020, Clinical lung cancer.

ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of Thoracic Oncology.

Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC

D. Gerber, H. Hamann, 2022, JTO clinical and research reports.

Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer.

D. Gerber, R. Brekken, D. Micklem, 2023, Lung cancer.

Assessing Barriers and Facilitators to Lung Cancer Screening: Initial Findings from a Patient Navigation Intervention.

D. Gerber, H. Hamann, David H Johnson, 2023, Population health management.

Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report

D. Gerber, J. Gagan, Brian D Reys, 2022, JTO clinical and research reports.

Phase I trial of intravenous fenretinide (4-HPR) plus safingol in advanced malignancies

D. Gerber, S. Awasthi, Min H. Kang, 2023, Cancer Chemotherapy and Pharmacology.

Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report

D. Gerber, J. Gagan, Melissa Mayer, 2022, JTO clinical and research reports.

Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).

T. Strom, D. Gerber, B. Burtness, 2017 .

Intracranial hemorrhage during GliaSite RTS manipulation in an anticoagulated patient

T. Chan, D. Gerber, S. Grossman, 2007, Journal of Radiotherapy in Practice.

Simultaneous acute myeloid leukemia and mesothelioma diagnoses in a long-term survivor of the 1984 Bhopal gas leak

D. Gerber, H. Naina, Jennie Y Law, 2014, Acta oncologica.

Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma

T. Batchelor, D. Gerber, S. Grossman, 2007, Cancer Chemotherapy and Pharmacology.

Implementation and Uptake of Rural Lung Cancer Screening.

D. Gerber, C. Brewington, Keith Argenbright, 2022, Journal of the American College of Radiology : JACR.

Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 Pandemic.

D. Gerber, M. Beg, Erin L Williams, 2021, JCO oncology practice.

Longitudinal Experience With and Impressions of COVID-19–Related Clinical Research Changes

C. Skinner, D. Gerber, M. Beg, 2021, JCO oncology practice.

Cancer Center Clinic and Research Team Perceptions of Identity and Interactions.

D. Gerber, T. Reimer, M. Gill, 2017, Journal of oncology practice.

Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines.

Xian-Jin Xie, D. Gerber, Jingsheng Yan, 2017, Journal of oncology practice.

Timing, Sites, and Correlates of Lung Cancer Recurrence.

D. Gerber, Jingsheng Yan, Hong Zhu, 2019, Clinical lung cancer.

Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition.

D. Gerber, D. Oliver, J. Sailors, 2017, Lung cancer.

A phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC)

L. Byers, D. Gerber, J. Lorens, 2016 .

Oncologic emergencies and urgencies: A comprehensive review

D. Gerber, D. Kyriacou, C. Baugh, 2022, CA: A Cancer Journal for Clinicians.

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

R. DiPaola, D. Gerber, C. Murphy, 2021, Cancer medicine.

Better Late Than Never: Fully Incorporating Oncology Advanced Practice Providers Into Cancer Clinical Trials.

D. Gerber, A. Denicoff, Erin L Williams, 2022, JCO oncology practice.

Application of Information Technology to Clinical Trial Evaluation and Enrollment

D. Gerber, Helen Mayo, Melanie A Hullings, 2021, JAMA Oncology.

Targeted Therapy in Non-small Cell Lung Cancer

D. Gerber, K. Rasul, A. Al-Khater, 2011 .

T-cell tolerant fraction as a predictor of immune-related adverse events

Yang Xie, D. Gerber, E. Wakeland, 2023, Journal for ImmunoTherapy of Cancer.

A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer.

T. Burns, S. Ramalingam, D. Gerber, 2014 .

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.

J. Milanowski, J. Aerts, R. Ramlau, 2023, Journal of Clinical Oncology.

MA 02.09 A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC

L. Byers, D. Gerber, D. Gibbons, 2017 .

Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.

R. Doebele, B. Solomon, D. Gerber, 2016 .

Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon

Jason Y. Park, Yang Xie, D. Gerber, 2020, The oncologist.

W. Curran, R. Jeraj, J. Bradley, 2017, Clinical lung cancer.

Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer.

D. Gerber, P. Bapsy, L. Dasappa, 2014, Lung cancer.

Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis

D. Gerber, Arjun Gupta, S. Khanna, 2019, Lung.

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

R. Greil, J. Milanowski, J. Aerts, 2023, The Lancet. Oncology.

A reevaluation of CD22 expression in human lung cancer.

Laurentiu M. Pop, Iliodora V. Pop, J. Minna, 2014, Cancer research.

Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial.

S. Abbara, D. Gerber, H. Hamann, 2017, Contemporary clinical trials.

Taking It to the States: Adapting Information Blocking Legislation to Oncology.

D. Gerber, 2023, Journal of Clinical Oncology.

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer

L. Sequist, A. Shaw, R. Heist, 2014 .

A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS

J. Berlin, M. Hidalgo, P. LoRusso, 2017, The oncologist.

A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC).

Yulei N. Wang, D. Gerber, J. Schiller, 2014 .

Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505).

W. Curran, R. Jeraj, J. Bradley, 2017 .

Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors

Yang Xie, D. Gerber, Jiong Cai, 2022, Cancer Immunology, Immunotherapy.

Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

D. Gerber, P. Swanson, A. Dowlati, 2017, Lung cancer.

An Updated Report on the Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer in the Surveillance, Epidemiology, and End Results Program.

D. Gerber, C. Murphy, G. Tortolero, 2023, JAMA oncology.